PLIANT Therapeutics Q2 2026 Results: Strong Oncology Trial, Lower Losses & $160M Cash
Learn how Pliant Therapeutics’ Phase 1b “FORTIFY” trial advances integrin‑based cancer therapy, cuts R&D costs, and plans 2028 funding strategy.
2 minutes to read
PLIANT THERAPEUTICS INC
Pliant Therapeutics Leads Innovation in Fibrotic Disease Research at ATS Conference
Pliant Therapeutics, Inc. is a San Francisco-based biopharmaceutical company at the forefront of fibrotic disease research, with a focus on developing innovative therapies for challenging conditions.
3 minutes to read